Search
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawncholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsEmbusartan
go.drugbank.com/drugs/DB19949ExperimentalEmbusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Embusartan has a monoisotopic molecular weight of 461.19 Da.
Categories: Angiotensin II Type 1 Receptor Blockers, Angiotensin II receptor antagonistsViloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesSynonyms: 2-((2-Ethoxyphenoxy)methyl)morpholineSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalfound to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigationalThe vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Synonyms: Recombinant stabilized RSV A prefusion F antigen, RSV subgroup A stabilized prefusion F proteinIcodextrin
go.drugbank.com/drugs/DB00702ApprovedInvestigationalIt is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways. … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease.
Mixtures: SOLUCIÓN DP PISA DXT, EXTRANEAL PERITONEAL DIALYSIS SOLUTION 75 g/lCategories: Compounds used in a research, industrial, or household settingTeclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerEcallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Hereditary angioedema is a rare autosomal dominant disorder with mutations to C1-esterase-inhibitor (C1-INH) located on Chromosome 11q, resulting in substantially lower levels of C4 and C1-INH activity
Categories: Drugs Used in Hereditary AngioedemaProducts: KALBITOR® 10 MG / MLVorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … of myocardial infarction (MI) or with peripheral arterial disease (PAD).
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamateTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalin March 2018. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].